Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,606.50GBp
4:04am EDT
Change (% chg)

-8.50 (-0.53%)
Prev Close
1,615.00
Open
1,615.00
Day's High
1,616.00
Day's Low
1,603.50
Volume
632,528
Avg. Vol
9,385,739
52-wk High
1,745.56
52-wk Low
1,446.50

Latest Key Developments (Source: Significant Developments)

Glaxosmithkline receives FDA approval for new self-injectable formulation of Benlysta
Friday, 21 Jul 2017 09:00am EDT 

July 21 (Reuters) - Glaxosmithkline Plc ::Receives FDA approval for a new self-injectable formulation of benlysta (belimumab) for systemic lupus erythematosus.Benlysta subcutaneous formulation will be available in specialty pharmacies in us in late August.Further regulatory submissions for subcutaneous formulation of benlysta under review, planned in other countries during course of 2017.  Full Article

GSK and Innoviva submit EU filing for extended use of Relvar Ellipta
Friday, 21 Jul 2017 09:00am EDT 

July 21 (Reuters) - GlaxoSmithKline plc ::GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination.  Full Article

Glaxosmithkline submits EU filing for Relvar Ellipta extension
Friday, 21 Jul 2017 08:51am EDT 

July 21 (Reuters) - Glaxosmithkline Plc ::Submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination.  Full Article

GSK to sell UK Horlicks business
Wednesday, 19 Jul 2017 07:30am EDT 

July 19 (Reuters) - Glaxosmithkline Plc ::Announces updates on UK manufacturing network.Proposals announced today for Worthing and Slough will result in a reduction of approximately 320 permanent jobs over next 4 years.Between now and 2020, plans to invest more than 140 mln stg at Ware, Hertfordshire, Barnard Castle, Co Durham, Montrose, Scotland sites.Investments will support expansion of manufacturing for respiratory and HIV medicines.In its consumer healthcare business, company intends to sell its Horlicks brand in UK.GSK is also exploring options to divest some other smaller non-core nutrition brands.Proposing to close associated manufacturing site in slough where UK product is made.None of announcements made today by company have resulted from UK's decision to leave European Union.In pharmaceuticals, co to undertake a strategic review of Cephalosporins antibiotics business.Company has also decided not to proceed with previously planned investment to build biopharmaceutical facility in Ulverston.  Full Article

GSK considering selling off its Horlicks business- BBC
Wednesday, 19 Jul 2017 05:58am EDT 

July 19 (Reuters) - :GSK is considering selling off its Horlicks business- BBC.  Full Article

Novartis CEO says growth at Alcon boosts options for eye surgery unit
Tuesday, 18 Jul 2017 02:00am EDT 

July 18 (Reuters) - Novartis Ag :Ceo reiterates entresto sales seen hitting $500 million in 2017.Ceo says expects ctl019 fda approval in pediatric all by october.Ceo says rising sales at alcon increase options for unit, including capital markets transaction.Ceo says don't expect big spike in rituxumab, etanercept biosimilars sales, but rather 'slow burn' following approval.Ceo says expects ongoing price pressure in generics.Ceo says glaxo joint venture is an asset for novartis that continues to appreciate, does not speculate when it would exercise put option.Ceo says plans to decide and announce pricing structure for ctl019 when drug is approved around october.  Full Article

GSK begins shipping quadrivalent vaccine doses to U.S. healthcare providers
Friday, 14 Jul 2017 04:56pm EDT 

July 14 (Reuters) - Glaxosmithkline Plc :Glaxosmithkline Plc says begun shipping quadrivalent vaccine doses to U.S. healthcare providers.Glaxosmithkline Plc says expects to supply up to 40 million doses across both vaccines for U.S. market in 2017-18 season.  Full Article

Glaxosmithkline says US regulatory submission for mepolizumab in EGPA
Wednesday, 28 Jun 2017 11:13am EDT 

June 28 (Reuters) - Glaxosmithkline Plc ::Announces US filing for mepo in EGPA.Submission of a supplemental biologics license application (SBLA) to United States Food and Drug Administration.Filing seeks approval of mepolizumab as an add-on therapy to corticosteroids for treatment of adult patients with eosinophilic granulomatosis with polyangiitis.Regulatory filings in other countries are planned during course of 2017 and 2018.  Full Article

Glaxosmithkline starts phase III study for nasal polyps drug
Tuesday, 27 Jun 2017 05:06am EDT 

June 27 (Reuters) - Glaxosmithkline Plc ::GSK starts phase III study with Mepolizumab in patients with nasal polyps.Key secondary endpoint is time to first actual surgery for nasal polyps by week 52​.Study is anticipated to complete in 2019.Study will assess efficacy and safety of subcutaneous Mepolizumab 100mg compared to placebo.  Full Article

GSK CEO Walmsley pursuing sale of Maxinutrition brand - Sky News
Thursday, 22 Jun 2017 03:33pm EDT 

June 22 (Reuters) - :Glaxosmithkline Plc CEO Emma Walmsley is pursuing a sale of Maxinutrition, a nutritional products brand - Sky News.  Full Article

BRIEF-GSK and Innoviva submit EU filing for extended use of Relvar Ellipta

* GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination Source text for Eikon: Further company coverage: